Leukemia, Myeloid, Acute: all 3,035 studies
Page 26 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyCompletedNCT01519596Not applicable
- Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral AzacitidineCompletedNCT01519011Phase 1
- Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid LeukemiaCompletedNCT01518556Phase 1/2
- Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid LeukemiaStatus unknownNCT01513109Phase 1/2
- Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative DisorderCompletedNCT01511575
- Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical TrialCompletedNCT01507441
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTerminatedNCT01500161Phase 2
- Administration of Donor T Cells With the Caspase-9 Suicide GeneActive, not recruitingNCT01494103Phase 1
- Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) PatientsTerminatedNCT01489722Phase 1
- A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for ThrombocytopeniaCompletedNCT01488565Phase 2
- Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)Status unknownNCT01488344Phase 1/2
- HLA-mismatched Microtransplantation for High Risk Acute Myeloid LeukemiaStatus unknownNCT01484171Phase 3
- Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell TransplantationWithdrawnNCT01483274Phase 1
- ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid LeukemiaWithdrawnNCT01478074Phase 1
- Protocol in Acute Myeloid Leukemia With FLT3-ITDCompletedNCT01477606Phase 2
- A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)CompletedNCT01468467Phase 1
- Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfilerTerminatedNCT01463410
- Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT01463046Phase 1
- Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)CompletedNCT01462578Phase 2
- PRO#0118: Decitabine Plus Mini Flu-BuCompletedNCT01455506Phase 1
- Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid LeukemiaTerminatedNCT01455025Phase 1
- Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01452646Phase 2
- Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)Status unknownNCT01451268Phase 1/2
- An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction ChemotherapyCompletedNCT01446081Phase 2
- Treatment of Relapsed or Refractory Acute Myeloblastic LeukemiaCompletedNCT01435343Phase 1/2
- Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeCompletedNCT01433965Phase 1
- Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid TumorsCompletedNCT01428427Phase 1
- ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDSStatus unknownNCT01423175Phase 2
- Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)CompletedNCT01422603Phase 1/2
- Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60aStatus unknownNCT01414231Phase 3
- Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531CompletedNCT01407757
- Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia PatientsCompletedNCT01398462Phase 1
- Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)CompletedNCT01397799Phase 1
- A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT01390337Phase 1
- Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell TransplantCompletedNCT01390311Phase 1
- NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)CompletedNCT01386619Phase 1/2
- MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid LeukemiaCompletedNCT01385787
- Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)CompletedNCT01385423Phase 1
- Biomarkers in Blood Samples From Patients With Acute Myeloid LeukemiaCompletedNCT01385150
- Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)CompletedNCT01382147Phase 3
- Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid LeukemiaCompletedNCT01380756Phase 1
- Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid LeukemiaCompletedNCT01373515Phase 1/2
- Treatment of Acute Leukemia Relapse After AllotransplantationStatus unknownNCT01369368Phase 1/2
- Unrelated Donor Stem Cell TransplantationCompletedNCT01364363Not applicable
- Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is PossibleCompletedNCT01361334Phase 2
- Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)CompletedNCT01352650Phase 1
- Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid LeukemiaCompletedNCT01347996Phase 4
- Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid LeukemiaCompletedNCT01332786Phase 1
- Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)Status unknownNCT01329471
- A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)CompletedNCT01324063Phase 3
- A Study Of Panobinostat In Children With Refractory Hematologic MalignanciesCompletedNCT01321346Phase 1
- Pre-hospital Risk Factors for Invasive Fungal InfectionStatus unknownNCT01315925
- RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AMLStatus unknownNCT01307241
- A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)Active, not recruitingNCT01305499Phase 2
- Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)CompletedNCT01301820Phase 2
- TXA127 in Enhancement of Engraftment in Adult Double Cord Blood TransplantationTerminatedNCT01300611Phase 1
- PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 YearsStatus unknownNCT01296178Not applicable
- Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT01295307Phase 2
- Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid LeukemiaCompletedNCT01290107
- Selecting a Favorable KIR Donor in Unrelated HCT for AMLCompletedNCT01288222Not applicable
- Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus unknownNCT01280786Phase 1
- PET-CT in AML for Detection of Extramedullary AML ManifestationsCompletedNCT01278069
- Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
- Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)TerminatedNCT01265199Phase 1
- Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid LeukemiaTerminatedNCT01260714Phase 1
- A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid LeukaemiaCompletedNCT01256073Phase 1
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal DiseaseCompletedNCT01249820Phase 2
- Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01249430Phase 1
- Biomarkers in Samples From Young Patients With Acute Myeloid LeukemiaCompletedNCT01247584
- Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)CompletedNCT01247493Phase 2
- Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CRTerminatedNCT01246752Phase 3
- Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01246622Phase 1
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)CompletedNCT01242774Phase 1
- Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 MutationCompletedNCT01237808Phase 3
- A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.CompletedNCT01236144Phase 1/2
- Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive ChemotherapyCompletedNCT01235572Phase 2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid LeukemiaTerminatedNCT01222143Phase 1/2
- Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)Status unknownNCT01211457Phase 1/2
- AHN-12 Biodistribution in Advanced LeukemiaTerminatedNCT01207076Phase 1
- Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)CompletedNCT01203033
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)TerminatedNCT01198054Phase 4
- Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)Status unknownNCT01195506
- Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 YearsTerminatedNCT01193400Phase 2
- Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AMLCompletedNCT01191957Phase 3
- Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and SurvivalStatus unknownNCT01188330Not applicable
- Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHLTerminatedNCT01187810Phase 1
- Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT01180426Phase 2
- Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With AzacitidineCompletedNCT01180322Phase 2
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesCompletedNCT01175785Phase 2
- Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT01174888Phase 1
- PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute LeukemiasCompletedNCT01169012Phase 1
- Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)CompletedNCT01167166Phase 1/2
- Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AMLCompletedNCT01161550Phase 1
- Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT01159301Phase 1
- Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDSCompletedNCT01159028Phase 1
- Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01154439Phase 1